Lundbeck Places Significant Bet On Myriad Alzheimer’s Candidate Flurizan
This article was originally published in The Pink Sheet Daily
Executive Summary
EU marketing partnership brings Myriad considerable royalties and milestones if compound wins approval as first drug to delay Alzheimer’s progression.
You may also be interested in...
Lundbeck/Myriad Marriage: Short But Not Sweet
Phase III data on Alzheimer’s disease candidate Flurizan comes up short.
Lundbeck/Myriad Marriage: Short But Not Sweet
Phase III data on Alzheimer’s disease candidate Flurizan comes up short.
NTB Measure Gains Ground In Alzheimer's
Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.